- Home
- PLGO vs HTFL Comparison
PLGO vs HTFL Comparison
Compare PLGO & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PLGO | HTFL |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2015 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PLGO | HTFL |
|---|---|---|
| Price | $25.27 | $50.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $38.20 |
| AVG Volume (30 Days) | 505.8K | ★ 2.4M |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $176,034,000.00 |
| Revenue This Year | N/A | $27.66 |
| Revenue Next Year | N/A | $23.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.92 |
| 52 Week Low | $20.85 | $20.13 |
| 52 Week High | $26.34 | $51.78 |
Technical Indicators
Market Signals| Indicator | PLGO | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 54.24 | 60.40 |
| Support Level | $24.19 | $24.30 |
| Resistance Level | $26.02 | $51.48 |
| Average True Range (ATR) | 0.43 | 2.32 |
| MACD | 0.10 | -0.87 |
| Stochastic Oscillator | 52.28 | 7.49 |
Price Performance
Historical ComparisonAbout PLGO Pelagos Insurance Capital Limited Common Shares
Pelagos Insurance Capital Ltd operates in the specialty insurance and reinsurance sector. Its activities include capital allocation, risk selection, and the deployment of capital through underwriting partnerships across insurance and reinsurance markets. The company manages a diversified portfolio and works with underwriting partners to provide insurance and reinsurance solutions to clients and brokers.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.